SPOTLIGHT -
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
Report: AI makes retinal imaging 100 times faster than manual method
First patient dosed in ViGeneron Phase 1b clinical trial of VG901 for the intravitreal treatment of RP